We examined the intracellular ph9sphorylation of 3'azido-3'-deoxythymidine (AZT)Jhd 2',3'-dideoxyinosine (ddl) and the effects on rNTP and dNTP pools when AZT and ddl were incubated separately and in combination in lymphocytes. We also compared the effect of adding ribavirin (RBV) to the two-drug combination of AZT + ddl.
Introduction
In the past decade the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS), has reached worldwide epidemic proportions. Some monotherapy regimens using antiretroviral drugs such as 3'-azido-3'-deoxythymidine (AZT) and 2',3'dideoxyinosine (ddl) have been used clinically to combat the disease (De Clercq, 1990; Schinazi et al., 1992; Hirsch and D'Aquila, 1993; Yarchoan et al., 1993) . However, the emergence of drug-resistant HIV strains Kemp, 1989; Kellam et aI., 1992; McLeod et al., 1992; Richman, 1992) and the problem of drug toxicity (Sommadossi et al., 1989; Cretton et al., 1991; Stagg et al., 1992) in treated patients could make combination chemotherapy an important choice for future treatment of AIDS (Cox, 1993; Caliendo and Hirsch, 1994) . Opportunistic infections also frequently occur in AIDS patients, who therefore require treatment for these infections in addition to treatment for HIV.
Many drug combinations have been studied in vitro. The combination of AZT and ddl was first shown by Schinazi et al. to exhibit, in vitro , synergistic inhibition of HIV (Schinazi et al., 1990; Dornsife et al., 1991) . These two nucleoside analogues rely on intracellular enzymes for metabolism to their active 5'-triphosphate forms, AZT-TP and ddA-TP respectively, which then inhibit reverse transcriptase (RT) (Furman et al., 1986; Hao et al., 1988; Huang et al., 1990; Tornevik et al., 1991; De Clercq, 1992) . In the case of AZT, the thymidine salvage pathway is responsible for the phosphorylation, whereas ddl is phosphorylated by a more complex pathway involving deoxyadenosine-metabolizing enzymes (summarized in Fig. 1) (Furman et al., 1986; Faulds and Brogden, 1992; Sommadossi, 1993) . The synergistic mechanism of the combination of AZT and ddl is, however, unknown. According to a recent study, RT is not synergistically inhibited by AZT-TP and ddA-TP in combination (White et al., 1993) , so the mechanism of synergy does not appear to lie at the level of RT per se.
Ribavirin (RBV) is a broad-spectrum antiviral drug effectiveagainstboth RNA and DNA viruses (Streeter et al., 1973; Sidwell et al., 1979; Gilbert and Knight, 1986) . RBV also enhances the anti-HIV activity of ddl when these two Hao et a/., 1988; Huang et sl., 1990; Balzarini et at. 1991b; Tornevik et a/., 1991; De Glercq, 1992). drugs are combined in vitro and in Vivo (Balzarini et al., 1990 (Balzarini et al., , 1991a , whereas it is antagonistic with AZT (Baba et al., 1987; Vogt et al., 1987) . These effects are thought to be a result of the effect of RBV on IMP and dTIP pools. RBV is known to inhibit IMP dehydrogenase (Streeter et al., 1973) , and causes an increase in IMP and dTIP pools and a decrease in GTP pools (Hartman et al., 1991) . An increase in the IMP pool would increase the phosphorylation of ddl,whereas an increase in the dTIP pool would, by feedback inhibition of thymidine kinase (TK), decrease the phosphorylation of AZT (summarized in Fig. 1 ).
In the present study, we investigated the intracellular metabolism of AZT and ddl separately and in combination
Effect of drugs on natural cellular rNTP pools
The effects of the combination of AZT and ddl, RBV alone, and a three-drug combination of AZT, ddl and RBV upon the rNTP pools of CEM cells are shown in Table 2 . The levels of rNTPs in cells incubated with the combination of AZT and ddl were similar to those in untreated control cells. There was a 40% reduction in GTP in CEM cells incubated with RBV alone compared to untreated cells. The same reduction in GTP was seen when cells were incubated with RBV in combination with AZT and ddl.
in order to examine whether the synergy seen between these two drugs could be related to changes in intracellular phosphorylation. We were also interested to examine the effects of RBV upon the combination of AZT and ddl, given the known effects of RBV upon the individual drugs as mentioned above. We therefore decided to compare the phosphorylation of AZT and ddl when used alone, in combination, and in a triple combination of AZT, ddl and RBV. We also investigated the effects of these drugs on the levels of natural deoxynucleoside triphosphate (dNTP) and ribonucleoside triphosphate (rNTP) pools.
Results

Effect of drugs on natural cellular dNTP pools
The dNTP pools of CEM cells incubated with the different drugs and drug combinations were measured by ion exchange HPLC, and their levels are shown in Table 1 . The levels of dNTPs in cells incubated with AZT, ddl, or the combination of AZT + ddl were similar to those in untreated cells. Cells incubated with RBV alone or with the three-drug combination of AZT, ddl and RBV exhibited a 40-50% increase in dTIP compared to untreated cells, but levels of the other dNTPs were similar to those in controls. Table 3 shows the phosphorylation of AZT and ddl when incubated alone or in combination in CEM cells. AZT was phosphorylated more efficiently than ddl. The level of AZT-TP formed was ca. 80-fold higher than that of ddA-TP. For both drugs, higher levels of the monophosphate were formed than of either the di-or triphosphates. When AZT and ddl were combined, there were 2-fold increases in the amounts of both ddA-DP and ddA-TP formed compared with cells incubated with ddl alone. However, the amount of AZT triphosphate formed in the combination of AZT + ddl was not different from that formed when cells were incubated with AZT alone.
Phosphorylation of AZT and ddl alone and in combination
Effect of RBV on the phosphorylation of the combination ofAZT +ddl.
The effect of RBV upon the cellular phosphorylation of the combination of AZT and ddl is shown in Table 4 . There was a 35% decrease in the amot# of total monophosphate formed (representing AZT-MP plus ddl-MP) when
RBV was added to the combination of AZT + ddl. However, the addition of RBV did not markedly affect the amount of AZT-TP or ddA-TP formed compared with the combination of AZT + ddl without RBV. No increase in the phosphory-RBV, AZT and ddl in combination 405 lation of ddl was seen when RBV was added to the combination of AZT + ddl.
Discussion
We investigated the phosphorylation of AZT and ddl when incubated separately and in combination in CEM cells. The effect of RBV upon the phosphorylation of AZT and ddl in combination was examined. The changes in cellular nucleotide pools brought about by these drug combinations were also determined. There were no appreciable changes in any of the cellular dNTP pools upon incubation of CEM cells with a clinically relevant concentration of 1 J.lM AZT or ddl separately or in combination. Previous studies on the effect of AZT on dNTP pools have shown different results, which may be explained by the different drug concentrations and cell types used (Furman et al., 1986; Frick et al., 1988; Hao et aI., 1988; Gao et al., 1993) . We did not see any effects upon dNTP pools despite using quite a high drug concentration and a long incubation time. These results agree with recent observations (Gao et al., 1993) which showed that 10 J.lM AZT or ddl has little effect on dNTP pools in resting or stimulated peripheral blood mononuclear cells.
The combination of AZT + ddl also had no effect on cellular rNTP pools. This is consistent with previous data showing AZT to be without an effect on rNTP pools (Cox, 0.050 ± 0.008 1991). The lack of effect of the combination of AZT + ddl upon dNTP or rNTP pools is consistent with observations that the toxicity of this combination is only additive and not synergistic (Schinazi et al., 1990; Dornsife et al., 1991) . AZT was phosphorylated more effectively than ddl at the same concentration. The level of AZT-TP formed was ca. 80-fold higher than that of ddA-TP. The affinities of HIV RT for AZT-TP and ddA-TP are similar (K, values of 0.1 and 0.2 11M, respectively (Hao et al., 1988) . The increased level of AZT-TP formed is therefore consistent with the higher antiviral activity of AZT compared to ddl in cell culture (Faulds and Brogden, 1992; Cox et al., 1994) . The results obtained here for the levels of AZT-TP and ddA-TP formed in CEM cells agree well with previous data on the phosphorylation of AZT and ddl in peripheral blood mononuclear cells (Gao et al., 1993) .
The phosporylation of ddl was increased 2-fold in the presence of AZT, whereas AZT phosphorylation was unchanged in the combination of AZT + ddl. There are a number of possible explanations for this increased phosphorylation of ddl in the presence of AZT. The uptake of ddl into the cells could be increased in the presence of AZT. AZT is known to enter cells by non-facilitated diffusion across the cell membrane (Zimmerman et al., 1987) . Alternatively, AZT or one of its metabolites could directly or indirectly affect the enzymes responsible for the phosphorylation of ddl. For example, AZT -MP (which is formed in large quantities) could act as the phosphate donor (substituting for IMP) during the initial phosphorylation of ddl to ddl MP, a reaction catalysed by the enzyme 5'nucleotidase (Fig. 1 ). Since incubation with the combination of AZT and ddl did not produce any change in GTP, which would be expected if IMP dehydrogenase were inhibited (Balzarini et al., 1991 a, b; Hartman et al., 1991) , it is unlikely that AZT increases ddl phosphorylation by the same mechanism as RBV, i.e. inhibition of IMP dehydrogenase.
AZT and ddl have been shown previously to be synergistic in combination against HIV replication (Schinazi et al., 1990; Dornsife etal., 1991) . The combination of AZT-TP and ddA-TP, however, does not produce synergy when tested against the RT (White et al., 1993) , indicating that the mechanism of synergy does not consist of interactions at the level of the RT. The increased activation of ddl in the presence of AZT shown here may explain, in part, the synergy of the combination of AZT + ddl. The 2-fold increase in ddl phosphorylation when combined with AZT shown here is similar to the increase in ddl phosphorylation found when ddl is combined with RBV (Hartman et al., 1991) , which is sufficient to cause synergy between ddl and RBV (Balzarini et al., 1991 a, b; Hartman et al., 1991) .
We also examined the effects of RBV, a known inhibitor of IMP dehydrogenase. Incubation with 10 11M RBV caused a 40% reduction in GTP and a 40-50% rise in dTIP pools, which is consistent with inhibition of IMP dehydrogenase. These observations are consistent with previous studies showing similar decreases in GTP and increases in dTIP at concentrations of 10-20 11M ribavirin (Balzarini et al., 1991 a, b; Hartman et al., 1991) . These effects of RBV were not altered by combination with AZT + ddl.
RBV has been shown to be synergistic in combination with ddl, but antagonistic in combination with AZT (Baba et al., 1987; Vogt et al., 1987; Balzarini et al., 1990 Balzarini et al., , 1991 . This has been attributed to the inhibition of IMP dehydrogenase by RBV, causing on the one hand increased phosphorylation of ddl (through increased IMP levels) and on the other hand decreased phosphorylation of AZT (through increased dTIP pools and feedback inhibition of thymidine kinase). We were interested to examine what effect RBV would have upon AZT + ddl in combination. The addition of 10 11M RBV to a combination of AZT + ddl (111M each) did not alter the phosphorylation of either AZT or ddl, even though the changes in the rNTP and dNTP pools indicated that IMP dehydrogenase was inhibited. This indicates that the phosphorylation of ddl in combination with AZT is already maximally stimulated and cannot be further increased by inhibition of IMP dehydrogenase.
In summary, the increase in ddl phosphorylation, leading to a 2-fold increase in the concentration of ddA-TP, in the presence of AZT may explain the synergy 'exhibited by this drug combination. However, the exact mechanism behind this increased activation of ddl remains to be determined. AZT and ddl in combination did not alter cellular nucleotide pools, suggesting that inhibition of IMP dehydrogenase is not responsible for the increased phosphorylation of ddl. The addition of 10 IlM RBV to a twodrug combination of 1 IlM each of AZT and ddl did not alter the phosphorylation of AZT and ddl. It would be of interest to examine the antiviral activity of this three-drug combination for synergy or antagonism. Our results indicate that it may be possible to combine RBV,AZT and ddl at certain concentrations, but further research is required to prove any benefit of such a combination. , specific activity of each 1320000 dpm nmol") and 10llM RBV (unlabelled). This concentration of RBV has been shown previously to be effective without causing cytotoxicity (Baba et a/., 1987; Balzarini et a/., 1990) . No drug toxicity was found when cells were counted and their viability assessed by the trypan blue exclusion method. We chose an incubation time of 20 h, since previous studies had shown the phosphorylation of AZT and ddl to reach a maximum at 15-20 h (Gao et a/., 1993) . The cells nearly doubled in concentration during this time, whilst none of the drugs at the concentrations used affected cell replication. After 20 h incubation at 37 DC, the cells were counted and then harvested by centrifugation at 1000 g for 10 min and extracted overnight with 60% cold methanol. Cell matter was removed by centrifugation at 1000 g for 10 min. The supernatant was carefully removed RBV, AZT and ddl in combination 407 by pasteur pipette and placed on ice. While maintaining the sample on ice, the methanol was reduced to half the volume by evaporation under nitrogen gas. The sample was then placed at -86 DC until frozen, followed by freeze-drying at -50 DC overnight. The dried sample precipitate was dissolved in 0.5 ml of cold distilled water. This method of extracting nucleotides has been shown to give excellent recoveries (Palmer and Cox, 1994) .
HPLC analysis
Analysis of ribonucleotides was performed by ion exchange high-performance liquid chromatography (HPLC) directly on cell extracts. Prior to analysis of dNTPs by HPLC, the ribonucleotides were degraded by periodate oxidation (Palmer and Cox, 1994; Tanaka et a/., 1984) . All samples, whether for cellular dNTP and drug metabolite measurement or cellular rNTP measurement, were then spun at 2000 g for 20 min in a refrigerated centrifuge. A 200-111 volume of the periodate-treated samples for measurement of dNTPs and drug metabolites, or a 100-111 volume of the samples for rNTP analysis was injected onto the HPLC. All HPLC analyses were performed on a chromatograph (Gilson Medical Electronics Inc.) equipped with a dual-wavelength spectrophotometer programmed to measure absorbance at 254 and 280 nm. All integration was performed on a Macintosh Classic II computer using RAININ Dynamax HPLC method manager software. Nucleotides were separated on a strong anion exchange column (Partisil 10 SAX, 250x4.6 mm I.D.; Whatman, Clifton, NJ, USA) using a phosphate buffer (KH 2P04 ) gradient-elution. The two buffers used were 0.02 M potassium phosphate (pH 3.5, buffer A) and 0.80 M potassium phosphate (pH 3.5, buffer B). The gradient was completed in four steps.
Step 1 was 100% buffer A for 5 min.
Step 2 was a 30-min linear increase in buffer B to 100%.
Step 3 was a constant isocratic 20-min delivery of 100% buffer B. In step 4, buffer B was decreased to 0% in 10 min. A constant flow of 1.3 ml min-i was used throughout. For analysis of drug metabolites, 30-s fractions were collected to which 10 ml of scintillation fluid was added. Radioactivity was then determined using a Beckman LS1801 scintillation counter. Peaks were identified by retention time on the chromatograph, the ratio of absorbance at 254 nm to that at 280 nrn, and comparison with known standards. Recoveries were calculated by comparisons of the peak areas of injected samples with those of pure dNTP standards of known concentrations.
